Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases
Authors:
- 3 April 2017
- journal article
- case report
- Published by Springer Nature in Frontiers of Medicine
- Vol. 11 (2) , 287-292
Abstract
Castleman disease (CD) is uncommon non-clonal lymphoproliferative disorder with unknown etiology. No standard therapy is recommended for relapsed/refractory CD patients, thus requiring development of novel experimental approaches. Our cohort of three adult patients with multicentric CD (MCD) were treated with refractory to traditional chemotherapy lenalidomide-containing regimens (10–25 mg lenalidomide perorally administered on days 1–21 in 28-day cycle) as second- to fourth-line treatment. Partial remission was achieved in first plasma-cell CD patient, who relapsed seven months after autologous hematopoietic stem cell transplantation and then failed to respond to four cycles of chemotherapy. Partial remission was obtained in second patient with CD and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. Third case showed complete remission with complete disappearance of pleural effusion and ascites and normalization of platelet count. To conclude, encouraging clinical responses were achieved in cohort of three patients with lenalidomide-based regimen, though long-term efficacy remains to be observed.We propose further investigation of therapeutic potential of this drug in treating MCD.Keywords
This publication has 34 references indexed in Scilit:
- Lenalidomide: a new treatment option for Castleman diseaseLeukemia & Lymphoma, 2011
- POEMS syndrome with severe neurological damage clinically recovered with lenalidomideHaematologica, 2011
- Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: Report of three casesJournal of the American Academy of Dermatology, 2011
- Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case reportJournal of Hematology & Oncology, 2009
- Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman diseaseBlood, 2007
- Lenalidomide therapy in a patient with POEMS syndromeBlood, 2007
- Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximabEuropean Journal of Haematology, 2005
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Rituximab therapy for HIV-associated Castleman diseaseBlood, 2003
- Prolonged remission of HIV-associated multicentric Castelmanʼs disease with an anti-CD20 monoclonal antibody as primary therapyAIDS, 2003